Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Purpose

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Condition

  • Hidradenitis Suppurativa (HS)

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female, 18 to 70 years of age - ≥6-month history of Hidradenitis suppurativa (HS) - Total AN (abscesse and inflammatory nodule) count ≥5 - HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III

Exclusion Criteria

  • Draining tunnel count >20 - Presence of another inflammatory condition or a skin condition that may interfere with study assessments - Known to have immune deficiency or is immunocompromised - Evidence or suspicion of active or latent tuberculosis - History of opportunistic, chronic, or recurrent infection requiring chronic antibiotic use, serious or life-threatening infection within 2 months, or had an infection requiring systemic antibiotics within 2 weeks - Has active systemic candidiasis - Unable to tolerate subcutaneous drug administration

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Tibulizumab Dose A
Subcutaneous injection
  • Biological: Tibulizumab Dose A
    Anti BAFF/IL-17 antibody. ZB-106
Experimental
Tibulizumab Dose B
Subcutaneous injection
  • Biological: Tibulizumab Dose B
    Anti BAFF/IL-17 antibody. ZB-106
Placebo Comparator
Placebo
Subcutaneous injection
  • Other: Placebo
    ZB-106 Placebo

Recruiting Locations

Medical Dermatology Specialists (Phoenix)
Phoenix 5308655, Arizona 5551752 85006
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

First OC Dermatology Research, Inc.
Irvine 5359777, California 5332921 92614
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Wallace Medical Group, Inc.
Los Angeles 5368361, California 5332921 90056
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

NorCal Clinical Research
Rocklin 5388319, California 5332921 95765
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Florida Academic Dermatology Center
Coral Gables 4151871, Florida 4155751 33134
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Georgia Skin & Cancer Clinic
Savannah 4221552, Georgia 4197000 31419
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

The Indiana Clinical Trials Center
Plainfield 4263108, Indiana 4921868 46168
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Equity Medical LLC (Kentucky)
Bowling Green 4285268, Kentucky 6254925 42104
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

DS Research of Kentucky, LLC
Louisville 4299276, Kentucky 6254925 40241
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

DelRicht LLC
Baton Rouge 4315588, Louisiana 4331987 70809
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Clinical Trials Management, LLC
Metairie 4333177, Louisiana 4331987 70006
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

MediSearch Clinical Trials
Saint Joseph 4407010, Missouri 4398678 64506
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Skin Cancer and Dermatology Institute
Sparks 5512862, Nevada 5509151 89436
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Equity Medical
New York 5128581, New York 5128638 10023
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

OptiSkin Medical
New York 5128581, New York 5128638 10128
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Optima Research
Boardman 5147784, Ohio 5165418 44512
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

ClinOhio Research Services
Columbus 4509177, Ohio 5165418 43213
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Apex Clinical Research Center
Mayfield Heights 5162188, Ohio 5165418 44124
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Palmetto Clinical Trial Services
Anderson 4569298, South Carolina 4597040 29625
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

DelRicht Research
Mt. Pleasant 4588165, South Carolina 4597040 29464
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

International Clinical Research - Tennessee LLC
Murfreesboro 4644312, Tennessee 4662168 37130
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

BRCR Global Texas
Katy 4702732, Texas 4736286 77450
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

DelRicht Research
Prosper 4720833, Texas 4736286 75078
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Progressive Clinical Research
San Antonio 4726206, Texas 4736286 78213
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

University of Washington Medical Center
Seattle 5809844, Washington 5815135 98164
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

Dermatology Specialists of Spokane
Spokane 5811696, Washington 5815135 99202
Contact:
Principal Investigator
702-825-9872
clinicaltrial@zurabio.com

More Details

Status
Recruiting
Sponsor
Zura Bio Inc

Study Contact

Chief Medical Officer
702-825-9872
clinicaltrial@zurabio.com